Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Initial results of the phase III BOSTON study

Meletios Dimopoulos • 22 May 2020
ASCO 2020
Multiple Myeloma Bortezomib Dexamethasone Selinexor
BOSTON

Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, gives an update on data from the BOSTON study (NCT03110562) – the first phase III study to evaluate the clinical benefit of selinexor with bortezomib and dexamethasone (SVd) for relapsed/refractory multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Meletios Dimopoulos

1:07
BelaRd trial: belamaf, lenalidomide, and dex in newly diagnosed MM
Meletios Dimopoulos • 10 Dec 2023
0:49
KdD vs Kd for R/R MM: renal subgroup analysis from CANDOR
Meletios Dimopoulos • 10 Dec 2023
1:19
Results of the PERSEUS trial: D-VRd with D-R maintenance in transplant-eligible newly diagnosed MM
Meletios Dimopoulos • 10 Dec 2023
1:34
iNNOVATE study update: long-term PFS in WM
Meletios Dimopoulos • 5 Dec 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals